Introduction
Vitiligo is an idiopathic and autoinflammatory disease of the skin affecting 1% of the population, characterized by depigmented macules and patches. The disorder generally manifests in childhood and young adulthood with almost half of the patients reported to be less than 20 years of age (1) . Although various topical and systemic agents have been used in the treatment of the disease, no consensus has been reached and as of yet there is no curative type of treatment. Phototherapy has been used in many diffuse dermatological diseases unresponsive to topical treatment agents as an alternative to systemic treatment methods, while its use is limited specifically in children due to early skin aging and potential skin cancer risks. Narrowband UVB (Nb UVB) treatment is commonly and successfully used in childhood for the treatment of psoriasis and atopic dermatitis and less frequently in the treatment of vitiligo (2) (3) (4) . The purpose of this study was to retrospectively evaluate the efficacy and short-term safety of Nb UVB in children diagnosed with vitiligo. Data were summarized and organized into tables and analyzed using descriptive statistics, given as mean ± standard deviation, median, minimum, maximum, and percentages.
Results
Clinical demographic properties of the patients and parameters of the treatment are summarized in Table 1 . The 26 children included 14 females and 12 males who received Nb UVB treatment. The age when the disorder started varied between 2 and 18 years with a mean age at onset of 10.07 ± 4.53 years. The duration of the disease prior to Nb UVB varied between 6 months and 10 years with a mean length of 3.15 ± 2.86 years. According to the Fitzpatrick classification, 20 patients had skin type 2 (76.9%), four had skin type 1, and three had skin type 3. The most commonly seen subtype of vitiligo was generalized vitiligo in 16 (61.5%) of the cases, and the remaining subtypes were focal vitiligo in four and acrofacial vitiligo in six cases. There was no patient with segmental vitiligo. Three of the 26 patients had presence of the thyroid antibody alone, and three had thyroid hormone disorder. Twenty patients had no thyroid disease. Folic acid deficiency, vitamin B12 deficiency, low hemoglobin, and ferritin deficiency accompanied the diagnoses in two, one, three, and two cases, respectively. All patients had used topical treatment agents prior to Nb UVB phototherapy. Topical steroids alone; topical steroids and topical calcipotriol; topical steroids and topical immunomodulator treatment; topical steroids, topical calcipotriol, and topical immunomodulator treatment; and cosmetic creams were used in six, three, six, four, and seven cases, respectively. Five of 26 patients dropped out of the treatment of their own will, while 19 completed the treatment according to the response and two patients are still continuing the treatment course. 
Discussion
Many types of noncurative treatment have been used in the management of vitiligo. Topical steroids are inexpensive, easy to apply, and may be effective in cases of limited involvement; however long-term use of steroids is not recommended due to the risk of skin atrophy (7, 8) . Topical calcipotriol, on the other hand, has been suggested as an alternative to potent steroids, rather than its solo use (8) . Oral psoralen plus ultraviolet A (PUVA) treatment is not recommended in children under 12 years of age due to its phototoxicity risk (9) . Topical PUVA may be used in children with an involvement of less than 20% of the body surface and is a safe method of treatment (10) .
Use of Nb UVB phototherapy was first reported in the management of vitiligo in 1997 and it was found to be superior to topical PUVA treatment (11). Njoo et al. reported Nb UVB use in children to be an efficient and safe method (12) Table 2 . The rate of repigmentation of 75% (47.36%) was compatible with the rates of repigmentation reported in the studies of Njoo et al. (12) and Brazzelli et al. (6) . The repigmentation rate was found to be higher in the present study in spite of the lower cumulative dose, different from the results in the study by Percivalle et al., who found a repigmentation rate of 14.3% in spite of a higher cumulative dose (14) . Although the duration of treatment was long, the reason for the lower cumulative dose may be due to continuous dose reduction and thus inadequate dose increases were secondary to the incompatibility of the patients to treatment. In the literature, complete and good response rates (>75% repigmentation) in pediatric cases with vitiligo have been reported to vary between 14.3% and 75%. This rate was found to be 47.36% in the present case series. No side effects were observed, except in one patient who had reversible erythema of the chin.
In conclusion, our study suggests that Nb UVB phototherapy seems to be a well-tolerated, effective, and safe method of treatment in the short term for pediatric patients, especially patients unresponsive to topical agents or with diffuse lesions. However, its long-term potential risks, such as photocarcinogenesis and photoaging, should be kept in mind while planning treatment. 
